A study to assess the pharmacokinetics and safety of Budesonide, Glycopyrronium, & Formoterol (BGF) metered dose inhaler (MDI) Hydrofluoroolefin (HFO) with a spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) with a spacer (Treatment A), as well as BGF MDI HFO without a spacer (Treatment C).

Trial Identifier: D5985C00008
Sponsor: AstraZeneca
Collaborator:
Parexel
NCTID:: NCT06297668
Start Date: April 2024
Primary Completion Date: June 2024
Study Completion Date: June 2024
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
DE Berlin, DE, 14050
GB Harrow, GB, HA1 3UJ